Selective inhibition of IL-17A: selective inhibition of IL-17A, as seen with secukinumab and ixekizumab, may disrupt immune balance by permitting overexpression of other IL-17 isoforms, such as IL-17C, that are produced by epithelial cells and implicated in the pathogenesis of both Pso and AD [29,30]. Here, IL17A is linked to Alzheimer disease.